Curis to Present at Skin Cancer Symposium
Monday March 14, 8:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 14, 2005--Curis, Inc. (NASDAQ: CRIS - News) announced today that Dr. Lee Rubin, Curis' Senior Vice President of Research and Chief Scientific Officer, will present an overview of inhibitors of the Hedgehog signaling pathway and their potential as therapeutics agents to treat basal cell carcinoma and other cancers at the Bay Area Skin Cancer Symposium scheduled for Thursday, March 17, 1:15-5:30 pm at the Mission Bay Gladstone Institutes in San Francisco, California.
Basal cell carcinoma, a skin cancer, is the most common form of all human cancers with approximately 800,000 to 1,000,000 new cases every year in the United States. To date, preclinical evidence indicates that inhibition of the Hedgehog pathway in basal cell carcinoma results in the selective and specific death of the tumor cells while conferring no harm to adjacent normal cells.
The symposium is sponsored by the Transplant Skin Cancer Program Project Grant, the Cutaneous Oncology Program of the Comprehensive Cancer Center, and the Department of Dermatology at the University of California at San Francisco.
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under partnership with Genentech, which also includes a co-development collaboration between Curis and Genentech for a basal cell carcinoma product candidate), kidney disease (licensed to Ortho Biotech, a subsidiary of Johnson & Johnson), neurological disorders (partnered with Wyeth Pharmaceuticals), hair growth, and cardiovascular disease. For more information, please visit the Curis web site at www.curis.com. |
